Indivior Plc Spon (NASDAQ:INVVY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Friday.

According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “

Shares of Indivior Plc Spon (NASDAQ INVVY) traded down 0.57% during mid-day trading on Friday, reaching $26.30. The company had a trading volume of 1,315 shares. Indivior Plc Spon has a 52-week low of $17.18 and a 52-week high of $26.53. The company has a market capitalization of $3.79 billion and a PE ratio of 47.39. The company’s 50-day moving average price is $22.17 and its 200-day moving average price is $21.16.

WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/11/zacks-investment-research-upgrades-indivior-plc-spon-invvy-to-hold.html.

Get a free copy of the Zacks research report on Indivior Plc Spon (INVVY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Indivior Plc Spon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior Plc Spon and related companies with MarketBeat.com's FREE daily email newsletter.